An Open-Label Study of Doxazosin Extended-Release for PTSD: Findings and Recommendations for Future Research on Doxazosin
Authors:
- 1 January 2018
- journal article
- research article
- Published by American Psychiatric Association Publishing in FOCUS
- Vol. 16 (1) , 67-73
Abstract
The authors present findings from an eight-week, open-label study of doxazosin extended-release for nightmares, sleep disturbance, and overall clinical symptoms in posttraumatic stress disorder (PTSD). Eight participants completed eight weeks of study treatment. The findings indicate that doxazosin may be of value for some individuals with PTSD but problematic for others. Objective:This report presents findings from an eight-week, open-label study of doxazosin extended-release for nightmares, sleep disturbance, and overall clinical symptoms in posttraumatic stress disorder (PTSD). Recommendations for future studies of doxazosin are provided.Method:Fifteen male and female adults were enrolled. The primary endpoints were change in Clinician-Administered PTSD Scale total, nightmare, and sleep disturbance scores from pretreatment to end of treatment. Self-report data on PTSD, sleep quality, depression, and quality of life collected at three time points and sleep diary data collected daily were analyzed secondarily.Results:Eight participants completed eight weeks of study treatment. Among completers, significant changes in nightmares and overall PTSD symptoms were found. Secondary analyses using data from completers and noncompleters demonstrated improvements in all secondary outcomes. Of the participants who dropped out of the study, four participants discontinued because of s...Keywords
This publication has 20 references indexed in Scilit:
- Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosinDrug and Alcohol Dependence, 2017
- Higher Pretreatment Blood Pressure Is Associated With Greater Posttraumatic Stress Disorder Symptom Reduction in Soldiers Treated With PrazosinBiological Psychiatry, 2016
- Doxazosin, an α-1-adrenergic-receptor Antagonist, for Nightmares in Patients with Posttraumatic Stress Disorder and/or Borderline Personality Disorder: a Chart ReviewPharmacopsychiatry, 2016
- The Skillings–Mack Test (Friedman Test when There are Missing Data)The Stata Journal: Promoting communications on statistics and Stata, 2009
- Autonomic Activation During Sleep in Posttraumatic Stress Disorder and Panic: A Mattress Actigraphic StudyBiological Psychiatry, 2009
- Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorderPsychoneuroendocrinology, 2008
- Change in posttraumatic stress disorder symptoms: Do clinicians and patients agree?Psychological Assessment, 2008
- The Pittsburgh sleep quality index: A new instrument for psychiatric practice and researchPsychiatry Research, 1989
- Pharmacokinetic overview of doxazosinThe American Journal of Cardiology, 1987
- Internal consistencies of the original and revised beck depression inventoryJournal of Clinical Psychology, 1984